Cyclophosphamide → AC regimen

HRID 904611

반응식

HRID 904611 반응식
[CH3:1][C@@H:2]1[O:7][C@@H:6]([O:8][C@@H:9]2[C:14]3=[C:15]([OH:32])[C:16]4[C:28](=[O:29])[C:27]5[C:22](=[CH:23][CH:24]=[CH:25][C:26]=5[O:30][CH3:31])[C:20](=[O:21])[C:17]=4[C:18]([OH:19])=[C:13]3[CH2:12][C@@:11]([OH:37])([C:33]([CH2:35][OH:36])=[O:34])[CH2:10]2)[CH2:5][C@H:4]([NH2:38])[C@@H:3]1[OH:39].C[C@@H]1O[C@@H](O[C@@H]2C3=C(O)C4C(=O)C5C(=CC=CC=5OC)C(=O)C=4C(O)=C3C[C@@](O)(C(CO)=O)C2)C[C@H](N)[C@@H]1O.Cl.[CH2:80]1[CH2:86][O:85][P:83]([N:87]([CH2:91][CH2:92][Cl:93])[CH2:88][CH2:89][Cl:90])(=[O:84])[NH:82][CH2:81]1>C(Cl)(Cl)Cl>[CH2:80]1[CH2:86][O:85][P:83]([N:87]([CH2:91][CH2:92][Cl:93])[CH2:88][CH2:89][Cl:90])(=[O:84])[NH:82][CH2:81]1.[CH3:1][C@@H:2]1[O:7][C@@H:6]([O:8][C@@H:9]2[C:14]3=[C:15]([OH:32])[C:16]4[C:28](=[O:29])[C:27]5[C:22](=[CH:23][CH:24]=[CH:25][C:26]=5[O:30][CH3:31])[C:20](=[O:21])[C:17]=4[C:18]([OH:19])=[C:13]3[CH2:12][C@@:11]([OH:37])([C:33]([CH2:35][OH:36])=[O:34])[CH2:10]2)[CH2:5][C@H:4]([NH2:38])[C@@H:3]1[OH:39]

참가 물질

5

반응물 3

HCID 2907CyclophosphamideHCID 31703DoxorubicinHCID 443939Doxorubicin Hydrochloride

생성물 1

HCID 56841756AC regimen

시약·촉매·용매 1

HCID 6212Chloroform용매

실험 절차

To a dark orange solution of Doxorubicin (0.036 g), prepared from Doxorubicin hydrochloride as described in the previous experiment, in chloroform (100 ml) were added while stirring at 50° PLA (4.048 g), cis-Pta2Cl2 (0.495 g) and cyclophosphamide (0.381 g in 40 ml dichloromethane). The mixture was transferred to a 500 ml ball mill jar about one-third filled with pebbles, rotated overnight and worked up as reported in Example 1 to give two samples of average particle sizes of 250-425μ and 150-250μ.

후처리

  1. additionwere added
  2. additionfilled with pebbles
  3. customto give two samples of average particle sizes of 250-425μ and 150-250μ

출처 및 근거

ORD 기록
ord-0ecf59725b2b46b29e17cb5bd3d85d29
출처 데이터셋
uspto-grants-1983_12
특허 번호
US04419340

연결된 노트

불러오는 중…